Sierra oncology stock yahoo finance
Sierra Oncology is an ambitious clinical stage drug development company located in Vancouver, BC and San Francisco, CA. Sierra Oncology (SRRA) dividends, SEC filings, and ... Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focuses on advancing targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. SRRA News Today (Sierra Oncology) | MarketBeat Sierra Oncology Announces Pricing of $103 Million Public Offering of Convertible Preferred Stock and Warrants finance.yahoo.com - November 7 at 1:00 PM Sierra Oncology and Gilead Sciences Agree on Amendments to Asset Purchase Agreement for Momelotinib Sierra Oncology | Investor Relations - Investor Relations Sierra Oncology to Hold Year End 2019 & 2020 Outlook Analyst & Investor Call Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially
Sierra Oncology, Inc. (SRRA) - Yahoo Finance
Did Sierra Oncology, Inc. (NASDAQ:SRRA ... - Yahoo7 Finance Jul 15, 2019 · Sierra Oncology is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.. Does Sierra Oncology Boast High Insider Ownership? For a common shareholder, it is worth checking how many shares are held by company insiders. Sierra Oncology | Targeted Cancer Treatments | Careers Sierra Oncology is a drug development company advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. We are led by a senior management team with a proven track record in research, clinical operations, product development, regulatory affairs and business development. Sierra Oncology Sees Hammer Chart Pattern: Time to Buy?
Jan 22, 2020 · Sierra Oncology previously reported its cash and cash equivalents totaled $67.7 million as of September 30, 2019, and that subsequently it had closed an underwritten public offering with gross
Sierra Oncology, Inc. Common Stock (SRRA) Financials | Nasdaq Find the latest Financials data for Sierra Oncology, Inc. Common Stock (SRRA) at Nasdaq.com. Sierra Oncology, Inc. (SRRA) - Yahoo7 Finance Get all the key statistics for Sierra Oncology, Inc. (SRRA), including valuation measures, fiscal year financial statistics, trading records, share statistics and more.
Find the latest Sierra Oncology, Inc. (SRRA) stock quote, history, news and other vital information to help you with your stock trading and investing.
Find out the direct holders, institutional holders and mutual fund holders for Sierra Oncology, Inc. (SRRA).
Sierra Oncology | Targeted Cancer Treatments | Home
View 13F filing holders of Sierra Oncology. Netflix Weathers the Storm 03/23/ 2020; Michael Burry's Scion fund averaged down on battered Tailored Brands. View today's stock price, news and analysis for Sierra Oncology Inc. (SRRA). Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation and Sukhi Jagpal MBA, CPAChief Financial Officer. Stock analysis for Sierra Oncology Inc (SRRA:NASDAQ GM) including stock price , stock chart, company news, key statistics, fundamentals and company profile. 21 Mar 2020 Yahoo Finance is a media platform that provides financial news, data about stock quotes, press releases, and financial reports. And all the data
1 Wall Street analysts have issued 1-year price objectives for Sierra Oncology's shares. Their forecasts range from $1.20 to $1.20. On average, they anticipate Sierra Oncology's stock price to reach $1.20 in the next twelve months. This suggests that the stock has a possible downside of 86.7%. View analysts' price targets for Sierra Oncology.